Microbix Biosystems
Microbix | Trusted manufacturer of infectious disease antigens.
Launch date
Employees
Market cap
CAD47.9m
Enterprise valuation
CAD41m (Public information from Sep 2024)
Share price
CAD0.35 MBX.TO
Toronto Ontario (HQ)
Financials
Estimates*
| CAD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 10.5m | 18.6m | 19.1m | 16.5m | 24.6m | 28.5m | 38.4m |
| % growth | (22 %) | 77 % | 3 % | (13 %) | 49 % | 16 % | 35 % |
| EBITDA | <1m | 5.7m | 3.7m | (1.1m) | 5.0m | 5.7m | 10.2m |
| % EBITDA margin | 2 % | 30 % | 20 % | (7 %) | 20 % | 20 % | 26 % |
| Profit | (6.2m) | 3.2m | 1.8m | (<1m) | - | - | - |
| % profit margin | (59 %) | 17 % | 9 % | - | - | - | - |
| EV / revenue | 2.8x | 4.6x | 3.7x | 2.5x | 2.1x | 1.8x | 1.4x |
| EV / EBITDA | 174.9x | 15.0x | 18.9x | -37.6x | 10.5x | 9.2x | 5.2x |
| R&D budget | 1.0m | 1.0m | 1.8m | 2.0m | - | - | - |
| R&D % of revenue | 10 % | 6 % | 9 % | 12 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
| N/A | N/A | IPO | |
| N/A | $88.1k | Post IPO Equity | |
| N/A | $296k | Post IPO Equity | |
| N/A | $248k | Post IPO Equity | |
| N/A | $1.5m | Post IPO Debt | |
* | $3.2m | Post IPO Debt | |
| Total Funding | - | ||
Related Content
Recent News about Microbix Biosystems
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.